INO — Inovio Pharmaceuticals, Inc.

Why people talked about INO (2026-10-31)

• The FDA granted accelerated approval for Voceryq, the first plasmid DNA-based immunotherapy for recurrent respiratory papillomatosis.
• Inovio's stock surged more than 120% in after-hours trading following the announcement of the regulatory approval.
• The significant price movement was driven by the successful market entry of the new treatment for adults with the condition.